Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm Corporation ("Aradigm" or the "Company") (OTC BB:ARDMD.OB) is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.

Aradigm expects its shares to begin trading on NASDAQ on Wednesday, June 11, 2014. The Company will trade under the ticker symbol "ARDM."

"The move to NASDAQ is a significant milestone for Aradigm and underscores our commitment to grow the value of our Company and broaden our shareholder base," said Igor Gonda, President and CEO of Aradigm Corporation. "As we continue to build on the positive momentum generated throughout this year with the start of our ORBIT-3 and ORBIT-4 Phase III clinical trials with Pulmaquin® for bronchiectasis and our recent QIDP designation from FDA for Pulmaquin for this disease, we are very pleased to begin trading on NASDAQ. We believe it will provide more liquidity for our shareholders. The strong fundamentals of the Company together with the increased visibility that NASDAQ will provide should assist us in maximizing shareholder value over the short and long term."

"We welcome Aradigm Corporation to the NASDAQ family of listed healthcare companies," commented Robert H. McCooey, Jr., Senior Vice President of New Listings and Capital Markets, NASDAQ OMX. "Aradigm embodies the strategic vision and innovative thinking that characterizes our listed companies. We congratulate Aradigm on its listing on the NASDAQ Capital Market and look forward to supporting their continued success."


Aradigm Corporation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Face masks protect from COVID-19 and other respiratory illnesses